Navigation Links
Lesaffre Invests in Intralytix, a US Biotechnology Company
Date:7/24/2017

BALTIMORE, July 24, 2017 /PRNewswire/ --Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest.

As a global key player in yeasts and fermentation, Lesaffre designs manufactures and markets innovative solutions for baking, food taste & pleasure, health care, and biotechnology. This new investment is perfectly in line with Lesaffre's ongoing expansion strategy in nutrition and health. In 2015, Lesaffre had already announced the investment in Gnosis, an Italian company specialized in ingredients for the pharmaceutical, nutraceutical, cosmetic and veterinary industries.

Alexander Sulakvelidze, Executive Vice President and Chief Scientific Officer of Intralytix commented:"We are delighted to have partnered with Lesaffre. This investment solidifies Intralytix's position as the leader in the field of bacteriophage research and commercialization, and allows us to strengthen the company infrastructure by enhancing our already superb R&D programs, adding high throughput robotic technologies, and expanding our state-of-the-art phage production capabilities."

Antoine Baule, Lesaffre's CEO, added "We believe that bacteriophage technology, mastered by Intralytix, offers an exciting platform for developing various antimicrobial products that will help reduce antibiotic resistance.  Intralytix is the leader in this field, and we look forward to working with their teams, developing new phage-based products and technologies and making them available to benefit customers worldwide."

"We are pleased to partner with Lesaffre and to engage in the development of a series of novel bacteriophage-based products," remarked John Woloszyn, Intralytix's CEO. "Phage-based products, when properly formulated and manufactured, provide a safe, effective and all-natural way to help maintain healthy microbiota. We believe that our collaboration with Lesaffre will significantly enhance and expedite product development and will ultimately benefit hundreds of thousands of people worldwide."

About Lesaffre

As a global key player in yeasts and fermentation, Lesaffre designs manufactures and markets innovative solutions for baking, food taste & pleasure, health care and biotechnology. The family group born in northern France in 1853, now a multi-national and a multicultural company, Lesaffre is committed to working with confidence to better nourish and protect the planet. In close collaboration with its clients and partners, Lesaffre employs 9,500 people in more than 70 subsidiaries, based in about 40 countries.

More information: www.lesaffre.com

About Intralytix, Inc.

Intralytix, Inc. is a privately-held company headquartered in Baltimore, Maryland. The company is the world's leader in bacteriophage technology and was the first company in the world to receive FDA-approval for a phage-based product for food safety applications. Intralytix currently has the largest portfolio in the world of phage-based products in commercial markets. The company holds several bacteriophage technology-related patents, including two U.S. patents (and additional patents pending) for fine-tuning human or animal microbiome by using bacteriophages to reduce or eliminate bacterial colonization.

More information: www.intralytix.com

Press contacts:

For Lesaffre
Vanessa Vazzaz
RP Carrées
Tel : +33 3 28 52 07 4
+33 6 34 32 24 23
vanessa.vazzaz@rp-carrees.co

For Intralytix
Dr. Alexander Sulakvelidze
Executive Vice President
Chief Scientific Officer
Tel. +1 410 625 2533
asulakvelidze@intralytix.com

 

View original content:http://www.prnewswire.com/news-releases/lesaffre-invests-in-intralytix-a-us-biotechnology-company-300493121.html


'/>"/>
SOURCE Intralytix, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Mitsui & Co. Invests Additional $CDN25 Million in BioAmber Sarnia
2. Ratan Tata Invests in Invictus Oncology
3. Goldman Sachs Invests US$20 Million in Ascletis
4. Connecticut Bioscience Innovation Fund Invests $10 Million in Program in Innovative Therapeutics for Connecticut’s Health (PITCH)
5. Portage Invests in Sentien Biotechnologies Inc.
6. Chiye Organic Silicon Material (Shanghai) Co., Ltd Invests USD1.6 Million on Production Plant
7. Infinity Group Invests US$4.2 M in Green BioTech Company BotanoCap
8. AMRESCO Invests in New Powder Manufacturing Facility to Support Growth in Life Science Business
9. Panitch Schwarze Life Sciences Practice Leader Speaks at Biotechnology Conference in Shanghai
10. Separation Systems for Commercial Biotechnology
11. Agricultural Biotechnology - Emerging Technologies & Global Markets - Driving Forces, Market Applications, Industry Structure & Competitive Dynamics - Research and Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/10/2019)... Md. (PRWEB) , ... April ... ... GenCure, both regenerative medicine manufacturing technology leaders, have locked into multiple agreements ... ever before. Companies across the regenerative medicine industry, ranging from synthetic biology ...
(Date:4/9/2019)... ... April 09, 2019 , ... ... increasing the capacity of life sciences organizations to accelerate innovation and maximize productivity, ... in the past 12 months. , USDM’s Cloud Assurance is ...
(Date:4/9/2019)... ... 2019 , ... The American Society of Gene & Cell Therapy (ASGCT) ... a new addition to the presidential line of succession, at the 22nd Annual ... leadership team for a three-year term (2019-2021). , All five incoming members of the ...
(Date:4/8/2019)... ... , ... US Capital Global Securities , an affiliate of US Capital ... privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has a pipeline of drugs ... dysfunction disorder and is ready to begin phase 2b trials. In phase 2a trials, ...
Breaking Biology Technology:
(Date:5/8/2019)... ... May 07, 2019 , ... ... an invitation-only community for world-class CIOs, CTOs, and technology executives. Modality ... engineering firm that guarantees confidence in a company’s cold chain. Subject-matter experts ...
(Date:5/7/2019)... (PRWEB) , ... May 07, 2019 , ... ... world’s first on-site Legionella DNA test in the UK. , In May, Landsec ... qPCR Legionella results in 45 minutes, enabling operators to take corrective action within ...
(Date:5/2/2019)... ... May 01, 2019 , ... uBiome, the leader in microbial ... Company’s General Counsel, as Interim Chief Executive Officer of uBiome, effective immediately. The ... leave. There will also be an independent investigation into uBiome’s billing practices to ...
Breaking Biology News(10 mins):